Cantor Fitzgerald analyst M. Goldstein now forecasts that the biopharmaceutical company will post earnings per share of ($5.05) for the year, down from their prior estimate of ($4.70). Canaccord Genuity has "Buy" rating and $85.0 target.
Among 9 analysts covering Radware (NASDAQ:RDWR), 6 have Buy rating, 0 Sell and 3 Hold. Zacks Investment Research upgraded shares of Radius Health from a "sell" rating to a "hold" rating in a research report on Tuesday, August 8th.
Currently Radius Health Cmn (NASDAQ:RDUS)'s shares owned by insiders are 0.26%, whereas shares owned by institutional owners are 0%. They noted that the move was a valuation call. The stock of Radius Health Inc (NASDAQ:RDUS) earned "Outperform" rating by Cowen & Co on Friday, May 6. Finally, Jefferies Group LLC reaffirmed a "hold" rating and issued a $38.00 price target (up from $34.00) on shares of Radius Health in a research note on Wednesday, August 9th. On Wednesday, February 24 the stock rating was downgraded by Jefferies to "Hold". The firm has "Hold" rating by Jefferies given on Thursday, November 2.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Week Herald and is owned by of Week Herald. If you are accessing this article on another publication, it was illegally stolen and republished in violation of USA and global trademark and copyright legislation.
Radius Health Cmn (NASDAQ:RDUS) shares traded 4.51% up during most recent session to reach at the closing price of $28.04. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.28) by ($0.03). The lowest target is $31.0 while the high is $90. The company has a quick ratio of 12.79, a current ratio of 12.87 and a debt-to-equity ratio of 0.53.
Radius Health (NASDAQ:RDUS) last released its quarterly earnings data on Thursday, November 2nd. The business had revenue of $13.50 million for the quarter, compared to the consensus estimate of $6.90 million. Major shareholders that own at least 10% of a company's stock are required to disclose their sales and purchases with the SEC. It also increased its holding in Cys Invts Inc (Put) (NYSE:CYS) by 750,000 shares in the quarter, for a total of 1.00 million shares, and has risen its stake in Public Svc Enterprise Group (NYSE:PEG). Granite Investment Partners Llc owns 297,228 shares or 1.07% of their U.S. portfolio. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
The stock increased 1.41% or $0.85 on November 17, reaching $61.3. About shares traded. Radware Ltd. (NASDAQ:RDWR) has risen 64.61% since November 17, 2016 and is uptrending. The disclosure for this purchase can be found here.
A number of large investors have recently bought and sold shares of RDUS. Ameritas Investment Partners Inc. raised its position in shares of Radius Health by 19.9% in the second quarter. Moreover, Ra Capital Management Llc has 2.58% invested in the company for 497,157 shares. Cubist Systematic Strategies LLC acquired a new stake in shares of Radius Health in the third quarter valued at about $110,000. Sei Investments Co. boosted its position in shares of Radius Health by 27.7% during the second quarter. Ameritas Investment Partners Inc. now owns 3,266 shares of the biopharmaceutical company's stock worth $148,000 after buying an additional 541 shares during the period. Farallon Capital Management Llc, a California-based fund reported 3.69 million shares.#img1#. The Maryland-based Rock Springs Capital Management Lp has invested 2.08% in the stock.
Investors wait Radius Health Inc (NASDAQ:RDUS) to report on February, 22. its quarterly earnings Wall Street analysts expect $-1.40 earnings per share, down $0.18 or 14.75 % from last year's $-1.22 same quarter earnings. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company's stock worth $144,000 after buying an additional 690 shares during the period.
Goldman Sachs Group Inc who had been investing in Radius Health Inc (Put) for a number of months, seems to be less bullish one the $1.25B market cap company. The Firm is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company's lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.